XML 31 R77.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaboration Agreements (Details) (USD $) In Thousands, unless otherwise specified | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Aug. 15, 2012 Licenses H5N1 licenses item | Dec. 14, 2011 Tianjing CanSino Biotechnology Inc. Technology Transfer Agreement item | Mar. 12, 2009 Tianjing CanSino Biotechnology Inc. Technology Transfer Agreement | Dec. 31, 2013 Tianjing CanSino Biotechnology Inc. Technology Transfer Agreement | Dec. 31, 2012 Tianjing CanSino Biotechnology Inc. Technology Transfer Agreement | Dec. 31, 2011 Tianjing CanSino Biotechnology Inc. Technology Transfer Agreement | Mar. 12, 2009 Tianjing CanSino Biotechnology Inc. Technology Transfer Agreement Minimum | Mar. 12, 2009 Tianjing CanSino Biotechnology Inc. Technology Transfer Agreement Maximum | Aug. 18, 2009 National Institutes of Health Patent License Agreement | Dec. 31, 2013 National Institutes of Health Patent License Agreement | Dec. 31, 2012 National Institutes of Health Patent License Agreement | Dec. 31, 2011 National Institutes of Health Patent License Agreement | Aug. 18, 2009 National Institutes of Health Patent License Agreement Minimum | Aug. 18, 2009 National Institutes of Health Patent License Agreement Maximum | Aug. 15, 2012 Medimmune Licenses H5N1 licenses item | Dec. 31, 2012 Medimmune Licenses H5N1 licenses | Dec. 31, 2013 Medimmune Licenses H5N1 licenses | Dec. 31, 2013 Medimmune Licenses H5N1 licenses Maximum
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, term |  |  |  |  |  | 8 years |  |  |  |  |  | 8 years |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  | $ 3,000 |  |  |  |  |  |  |  |  |  | $ 9,900
Amount of payment for transfer of an additional serotypes and related technology |  |  |  |  | 300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional serotypes transferred as per amended agreement |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development expenses | 8,384 | 17,044 | 9,007 |  |  |  | 0 | 200 | 0 |  |  |  |  |  |  |  |  |  |  |  |
Royalties included in the account payable and accrued liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,036 |
Milestone payments incurred |  |  |  |  |  |  | 1,200 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments incurred under the March 12, 2009 agreement |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments incurred under the December 14, 2011 agreement |  |  |  |  |  |  | 200 |  |  |  |  |  |  |  |  |  |  |  |  |  |
License issue royalty |  |  |  |  |  |  |  |  |  |  |  | 80 |  |  |  |  |  |  |  |  |
Licenses fees and royalties paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,400 |  |
Non-refundable annual royalty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 |  |  |  |  |
Royalty payments on net sales (as a percent) |  |  |  |  |  |  |  |  |  | 6.00% | 10.00% |  |  |  |  | 1.50% | 4.00% |  |  |  | 10.00%
Royalty payments upon achieving each benchmark |  |  |  |  |  |  |  |  |  |  |  |  | 330 |  |  |  |  |  |  |  |
License issue royalty recorded in research and development expenses |  |  |  |  |  |  |  |  |  |  |  |  | $ 21 | $ 8 | $ 8 |  |  |  |  |  |
Number of sublicense agreements with termination date revised |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |

X
- Definition Represents the amount of license issue royalty payable by the entity as per the agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementLicenseIssueRoyalty
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of royalty payments agreed to be paid upon achieving each benchmark, under the collaborative agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementLicenseRoyaltyPaymentsUponAchievementOfEachBenchmark
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of licenses fees and royalties paid by the entity as per the collaboration agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementLicensesFeesAndRoyaltiesPaid
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payments that will be made by the entity as per the collaboration agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePayments
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payments incurred by the entity as per the collaboration agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePaymentsIncurred
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of milestone payments incurred by the entity for the collaboration agreement before amendment. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePaymentsIncurredForAgreementBeforeAmendment
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of milestone payments incurred by the entity for the amended collaboration agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementMilestonePaymentsIncurredForAmendedAgreement
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of non-refundable annual royalty payable by the entity as per the agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementNonRefundableAnnualRoyalty
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of additional serotypes transferred as per amended collaboration agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementNumberOfAdditionalSerotypesTransferred
Namespace Prefix: | sva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount that will be paid by the entity as per the amended collaboration agreement for transfer of additional serotypes and related technology. + References No definition available. + Details
Name: | sva_CollaborativeArrangementsAndNoncollaborativeArrangementPaymentForTransferOfAdditionalSerotypesAndRelatedTechnology
Namespace Prefix: | sva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the length of time the collaborative agreement is in effect subject to terms specified within the agreement. + References No definition available. + Details
Name: | sva_CollaborativeArrangementTermOfAgreement
Namespace Prefix: | sva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of sublicense agreements with termination date revised. + References No definition available. + Details
Name: | sva_NumberOfSublicenseAgreementsRevsied
Namespace Prefix: | sva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty payments on net sales, expressed as a percentage, under collaborative agreement. + References No definition available. + Details
Name: | sva_RoyaltyPaymentOnNetSales
Namespace Prefix: | sva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765 + Details
Name: | us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration